BioLargo ( (BLGO) ) has released its Q3 earnings. Here is a breakdown of the information BioLargo presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BioLargo, Inc. is a Delaware-based company that invents, develops, and commercializes innovative platform technologies aimed at solving environmental challenges such as PFAS contamination, water treatment, and odor control. The company operates in the environmental technology sector and leverages its scientific and engineering expertise to bring disruptive technologies to market.
In its latest earnings report for the quarter ended September 30, 2025, BioLargo reported a significant net loss, primarily due to a credit loss expense from a customer’s contractual default. Despite this setback, the company continues to focus on its strategic initiatives and technological advancements.
Key financial highlights include a total revenue of $7.1 million for the nine months ended September 30, 2025, a decrease from the previous year. The company faced an operating loss of $10.8 million, with a notable credit loss expense of $3.8 million due to a customer’s default. BioLargo’s cash and cash equivalents increased to $4.5 million, supported by financing activities that provided $7.3 million in net cash.
Looking forward, BioLargo’s management remains focused on increasing revenues and securing additional financing to support its operations and technological investments. The company acknowledges the challenges ahead but is committed to leveraging its innovative solutions to drive future growth and market presence.